You just read:

Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Mar 05, 2019, 20:17 ET